- Home
- FLNG vs DYN Comparison
FLNG vs DYN Comparison
Compare FLNG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- DYN
- Stock Information
- Founded
- FLNG 2006
- DYN 1984
- Country
- FLNG Bermuda
- DYN United States
- Employees
- FLNG N/A
- DYN N/A
- Industry
- FLNG Marine Transportation
- DYN Medicinal Chemicals and Botanical Products
- Sector
- FLNG Consumer Discretionary
- DYN Health Care
- Exchange
- FLNG Nasdaq
- DYN Nasdaq
- Market Cap
- FLNG 1.3B
- DYN 1.4B
- IPO Year
- FLNG N/A
- DYN 2020
- Fundamental
- Price
- FLNG $24.00
- DYN $10.32
- Analyst Decision
- FLNG Hold
- DYN Strong Buy
- Analyst Count
- FLNG 1
- DYN 14
- Target Price
- FLNG $23.00
- DYN $44.57
- AVG Volume (30 Days)
- FLNG 375.4K
- DYN 2.6M
- Earning Date
- FLNG 08-13-2025
- DYN 08-11-2025
- Dividend Yield
- FLNG 12.50%
- DYN N/A
- EPS Growth
- FLNG N/A
- DYN N/A
- EPS
- FLNG 1.91
- DYN N/A
- Revenue
- FLNG $354,551,000.00
- DYN N/A
- Revenue This Year
- FLNG N/A
- DYN N/A
- Revenue Next Year
- FLNG $3.64
- DYN N/A
- P/E Ratio
- FLNG $12.57
- DYN N/A
- Revenue Growth
- FLNG N/A
- DYN N/A
- 52 Week Low
- FLNG $19.46
- DYN $6.36
- 52 Week High
- FLNG $28.27
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- FLNG 49.54
- DYN 34.25
- Support Level
- FLNG $23.69
- DYN $10.56
- Resistance Level
- FLNG $24.95
- DYN $15.23
- Average True Range (ATR)
- FLNG 0.58
- DYN 1.01
- MACD
- FLNG -0.01
- DYN -0.47
- Stochastic Oscillator
- FLNG 41.92
- DYN 4.10
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.